Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: hiv studies + hiv therapy + hiv  Related to the article below (Last Update: 8/5/2008)


eFluxMedia
Growth Hormone Reduces Abdominal Fat, Cardiovascular Risk In HIV ...
Science Daily (press release) -
A significant number of HIV-infected individuals receiving antiviral therapy develop lipodystrophy ? symptoms of which include excess fat deposits in the ...
Growth hormone may help some HIV patients Reuters
Daily Doses of Growth Hormone May Aid HIV Patients eFluxMedia
Growth Hormone Reduces Fat In HIV Patients With Abdominal Obesity Medical News Today
CBS2 Chicago - Science Daily (press release)
all 278 news articles »
New Data Shows HIV Therapy Tipranavir (Aptivus) Is Effective And ...
Medical News Today (press release), UK - 58 minutes ago
The company is involved in basic research in that area and is committed to improving HIV therapy by providing physicians and patients with innovative ...

Scientific American
AIDS therapy concerns found worldwide
Detroit Free Press, United States - Aug 4, 2008
A separate study, released over the weekend, shows that thousands more people are getting HIV each year than experts realized. The government's tally of the ...
AIDS Threat Still Looming Inside Costa Rica
all 1,252 news articles »

BBC News
TB hampers HIV treatment - study
BBC News, UK - Aug 3, 2008
Around 40% of HIV patients in the South African study were also treated for TB. In poorer countries, antiretroviral therapy is often initiated in TB clinics ...
HIV/Aids in southern regions poses great risk DailyNewsOnline
AIDS denial condemns S. Africans to avoidable death ABC Science Online
Efavirenz Superior to Nevirapine for Treating HIV in Coinfected ... DG News
Medical News Today - AFP
all 55 news articles »
Bionor Immuno Advances HIV Peptide-Based Therapeutic Immunization ...
MarketWatch -
"In previous clinical studies, this peptide therapeutic candidate has demonstrated promising results in T-cell stimulation of the immune system in HIV ...

TopNews
Long-term HIV treatment may reduce risk for atherosclerosis
EurekAlert (press release), DC -
"When we first prescribed highly active antiretroviral therapy for HIV in 1995, we were concerned about how these drugs changed lipid levels in patients and ...
Study highlights risky behavior, lack of care among HIV-infected ... EurekAlert (press release)
all 19 news articles »

Scientist Live
Landmark Global Survey Shows HIV-Positive Patients Still Fear ...
AllAfrica.com, Washington -
Respondents in North America were most concerned that their HIV-positive status could be damaging to their reputation. Study results show that concerns ...
New HIV Treatment Guidelines Issued Medscape (subscription)
Kaiser Daily HIV/AIDS Report Kaiser network.org
Africa: Aids Updates and Analysis AllAfrica.com
all 66 news articles »
Expansion of ARV programmes could reduce new HIV infections
Africa Science News Service, Kenya - 19 minutes ago
A Canadian study by the BC Centre for Excellence in HIV/AIDS (BC-CfE) reveals the dramatic impact that increased coverage with HIV therapy could have in ...

Canada.com
Progress but end of AIDS ?not in sight?
Business Day, South Africa -
And although the world had made tremendous strides in getting treatment to HIV-positive people ? 3- million of them in the developing world ? twice as many ...
Landmark Global Survey of People Living with HIV and AIDS Shows ... Earthtimes (press release)
HEALTH: Stepping Up the Response to AIDS Inter Press Service (subscription)
AIDS Conference In Mexico Opened For Discussions eFluxMedia
The West Australian - Journal of American Medical Association (subscription)
all 344 news articles »
Vaccine failures shake up HIV research
Chemistry World, UK -
Not far behind is biotech firm Gilead, which already dominates the HIV therapy market with Truvada and Atripla, and has now begun a Phase III clinical study ...
Source: Google News

… patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
FJ Palella Jr, KM Delaney, AC Moorman, MO Loveless … - N Engl J Med, 1998 - aids-clinical-care.highwire.org
... At week 24, 43 of 46 patients (96%) in Group Two had HIV-1 RNA <400 copies/ml, and
73% of Group One ... No study subject has discontinued therapy because of an ...

Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection -
DL Paterson, S Swindells, J Mohr, M Brester, EN … - Annals of Internal Medicine, 2000 - annals.highwire.org
... used in studies of antihypertensive agents and orally administered oncologic therapy
and in earlier studies of adherence to therapy in HIV-infected patients (15 ...

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, … -
A Carr, K Samaras, A Thorisdottir, GR Kaufmann, DJ … - Lancet, 1999 - ncbi.nlm.nih.gov
... lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. ... HIV Medicine
Unit and Centre for Immunology, St ... syndrome with long-term therapy for HIV ...

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. -
A Mocroft, S Vella, TL Benfield, A Chiesi, V … - Lancet, 1998 - ncbi.nlm.nih.gov
... infected with HIV-1. EuroSIDA Study Group ... Royal Free Centre for HIV Medicine and
Department ... The introduction of combination antiretroviral therapy and protease ...

[PDF] … on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV … -
B Ledergerber, M Egger, M Opravil, A Telenti, B … - Lancet, 1999 - infekt.ch
... 1 ? 7 3 . 2 1 Feinstein A. The role of observational studies in the evaluation of
therapy. ... formulation: a review of its use in patients with HIV infection ...

… of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV … -
A Carr, K Samaras, S Burton, M Law, J Freund, DJ … - AIDS, 1998 - aidsonline.com
... limbs and upper trunk), hyperlipidaemia and insulin resistance in patients receiving
potent HIV protease inhibitor therapy. Design: Cross-sectional study. ...

… antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV … -
G Greub, B Ledergerber, M Battegay, P Grob, L … - The Lancet, 2000 - Elsevier
... Most studies on the natural history of HCV-HIV-1 coinfection were done before potent
antiretroviral therapy became available, and when clinical progression was ...

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS … -
CC Carpenter, MA Fischl, SM Hammer, MS Hirsch, DM … - JAMA, 1997 - Am Med Assoc
... FULL TEXT. Limited Patient Adherence to Highly Active Antiretroviral Therapy for
HIV-1 Infection in an Observational Cohort Study Nieuwkerk et al. ...

… starting highly active antiretroviral therapy: a collaborative analysis of prospective studies -
M Egger, M May, G Ch?ne, AN Phillips, B … - The Lancet, 2002 - Elsevier
... Fast track ? Articles. Prognosis of HIV-1-infected patients starting highly active
antiretroviral therapy: a collaborative analysis of prospective studies *. ...

… Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV … -
B Autran, G Carcelain, TS Li, C Blanc, D Mathez, R … - Science, 1997 - sciencemag.org
... found over the 12-month study period between ... The HIV-related abnormalities in T cell
activation ... activation and viral load under triple antiretroviral therapy. ...

Source: Google Scholar
 

Studies target side effect of HIV therapy

Researchers think they've found drugs that won't rearrange the body fat of patients.
By Jia-Rui Chong, Times Staff Writer
February 27, 2007

Three new studies indicate that it may be possible to avoid many of the fat-distribution problems associated with HIV drug therapy, giving patients a better quality of life and minimizing risk to their hearts, researchers said Monday.

The introduction of powerful drug cocktails in the 1990s was a major breakthrough in HIV therapy, permitting patients to survive indefinitely.

But it was accompanied by an unanticipated side effect — a rearrangement of body fat that produced a withering of the arms and excessive accumulations of fat in the abdomen, back and neck, often referred to as buffalo hump.

In addition to the aesthetic problems, the changes altered cholesterol levels, potentially increasing the risk of heart attack and stroke.

Article continues below and (thank you)
 
Researchers at the Conference on Retroviruses and Opportunistic Infections at the Los Angeles Convention Center reported that many of the problems could be avoided by judicious use of an experimental drug, an existing AIDS medication and a widely used cholesterol-lowering agent.

"The message is a lot of work is going on to try to optimize treatment for the long haul," said Dr. Judith Currier, a professor of medicine at UCLA who was involved in one of the studies.

Dr. Steven Grinspoon of Massachusetts General Hospital reported on an ongoing study of an experimental drug called TH9507 that stimulates the body to produce a growth hormone, which burns off excess fat.

He studied 412 patients, half of whom received the drug in addition to their regular HIV therapy and half of whom received a placebo. The drug, manufactured by Theratechnologies Inc. of Montreal, reduced the buildup of fat in the abdomen and back by 15%.

Such buildup can be a serious problem, said Dr. Curtis Cooper of the University of Ottawa, because it often leads patients to abandon their drug regimen.

The drug also reduced blood levels of triglycerides — a major component of cholesterol — by 18%.

The cholesterol-lowering drug ezetimibe — sold by Merck & Co. and Schering-Plough Corp. as Zetia — gives doctors another option, said Dr. David Wohl of the University of North Carolina at Chapel Hill. He studied 48 patients, half of whom received Zetia in addition to their normal regimen.

Those who received the drug had a median 12% drop in low-density lipoproteins, the so-called bad cholesterol, while those receiving a placebo had a 3% increase. The study was funded in part by Merck.

In the third study, Dr. D. William Cameron of the University of Ottawa looked at two groups of HIV-positive patients who had previously received no treatment.

One of the groups initially received the Abbott Laboratories combination drug Kaletra in a cocktail with other drugs, then only Kaletra. The second group received a standard regimen.

Of those receiving Kaletra, 5% developed abnormal fat distribution, specifically the loss of fat in their limbs. In the comparison group, 34% suffered from the abnormal distribution, Cameron said.

Dr. Julian Falutz, director of the HIV Metabolic Clinic at McGill University in Montreal, said the presentations did not prompt him to make immediate changes in drug treatment, but he was encouraged by the data.

"I thought there were a lot of very positive results, which points out that people are taking metabolic issues very seriously and minimizing these complications," he said.
 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast